Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PYGB | P11216 | 7/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | HK2 | P52789 | 2/20 | 0.38 |
| ▸ | HK1 | P19367 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18390802 | 0.85 | KDM4E (0.42) | KDM4ELMNACYP2D6CYP2C19PYGB | |
| SCHEMBL30019948 | 0.84 | LMNA (0.54) | KDM4ELMNACYP2D6CYP2C19PYGB | |
| SCHEMBL1673868 | 0.84 | LMNA (0.54) | KDM4ELMNACYP2D6CYP2C19PYGB | |
| SCHEMBL1673864 | 0.84 | LMNA (0.54) | KDM4ELMNACYP2D6CYP2C19PYGB | |
| SCHEMBL3966078 | 0.84 | LMNA (0.54) | KDM4ELMNACYP2D6CYP2C19PYGB | |
| SCHEMBL18412154 | 0.82 | PYGB (0.42) | KDM4ELMNACYP2D6CYP2C19PYGB | |
| SCHEMBL17400176 | 0.81 | ALDH1A1 (0.56) | KDM4ELMNACYP2D6CYP2C19PYGB | |
| SCHEMBL12295742 | 0.81 | ALDH1A1 (0.56) | KDM4ELMNACYP2D6CYP2C19PYGB | |
| SCHEMBL13773326 | 0.81 | ALDH1A1 (0.56) | KDM4ELMNACYP2D6CYP2C19PYGB | |
| SCHEMBL20626631 | 0.81 | ALDH1A1 (0.56) | KDM4ELMNACYP2D6CYP2C19PYGB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215710-A1 | CARBOHYDRATE BASED TOLL-LIKE RECEPTOR (TLR) ANTAGONISTS | RELIANCE LIFE SCIENCES PVT. LTD. (IN) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215710-A1 | CARBOHYDRATE BASED TOLL-LIKE RECEPTOR (TLR) ANTAGONISTS | TLR4, TLR1, TLR2 | KDM4E 2402/4885LMNA 4669/4885CYP2D6 3144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.